Allergy Therapeutics suffers phase 3 birch allergy jab trial failureUK-based Allergy Therapeutics has suffered a setback after phase 3 results from the B301 trial of its latest Share XAllergy Therapeutics suffers phase 3 birch allergy jab trial failurehttps://pharmaphorum.com/news/allergy-therapeutics-suffers-phase-3-birch-allergy-jab-trial-failure/
